207 related articles for article (PubMed ID: 12431074)
1. The practical synthesis of a novel and highly potent analogue of bryostatin.
Wender PA; Baryza JL; Bennett CE; Bi FC; Brenner SE; Clarke MO; Horan JC; Kan C; Lacôte E; Lippa B; Nell PG; Turner TM
J Am Chem Soc; 2002 Nov; 124(46):13648-9. PubMed ID: 12431074
[TBL] [Abstract][Full Text] [Related]
2. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
4. The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.
Wender PA; DeBrabander J; Harran PG; Jimenez JM; Koehler MF; Lippa B; Park CM; Siedenbiedel C; Pettit GR
Proc Natl Acad Sci U S A; 1998 Jun; 95(12):6624-9. PubMed ID: 9618462
[TBL] [Abstract][Full Text] [Related]
5. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
Stanwell C; Gescher A; Bradshaw TD; Pettit GR
Int J Cancer; 1994 Feb; 56(4):585-92. PubMed ID: 8112895
[TBL] [Abstract][Full Text] [Related]
6. The rational design of potential chemotherapeutic agents: synthesis of bryostatin analogues.
Wender PA; Hinkle KW; Koehler MF; Lippa B
Med Res Rev; 1999 Sep; 19(5):388-407. PubMed ID: 10502742
[TBL] [Abstract][Full Text] [Related]
7. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.
Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE
Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938
[TBL] [Abstract][Full Text] [Related]
8. Chemistry and clinical biology of the bryostatins.
Mutter R; Wills M
Bioorg Med Chem; 2000 Aug; 8(8):1841-60. PubMed ID: 11003129
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin-1: a novel PKC inhibitor in clinical development.
Kortmansky J; Schwartz GK
Cancer Invest; 2003; 21(6):924-36. PubMed ID: 14735696
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum(II) by bryostatin 1.
Basu A; Lazo JS
Cancer Res; 1992 Jun; 52(11):3119-24. PubMed ID: 1591725
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a simplified bryostatin C-ring analogue that binds to the CRD2 of human PKC-alpha and construction of a novel BC-analogue by an unusual Julia olefination process.
Hale KJ; Frigerio M; Manaviazar S; Hummersone MG; Fillingham IJ; Barsukov IG; Damblon CF; Gescher A; Roberts GC
Org Lett; 2003 Feb; 5(4):499-502. PubMed ID: 12583753
[TBL] [Abstract][Full Text] [Related]
13. Selective binding of bryostatin analogues to the cysteine rich domains of protein kinase C isozymes.
Wender PA; Lippa B; Park CM; Irie K; Nakahara A; Ohigashi H
Bioorg Med Chem Lett; 1999 Jun; 9(12):1687-90. PubMed ID: 10397502
[TBL] [Abstract][Full Text] [Related]
14. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
15. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a murine leukaemia cell line resistant to the growth-inhibitory effect of bryostatin 1.
Prendiville J; McGown AT; Gescher A; Dickson AJ; Courage C; Pettit GR; Crowther D; Fox BW
Br J Cancer; 1994 Oct; 70(4):573-8. PubMed ID: 7917900
[TBL] [Abstract][Full Text] [Related]
17. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang H; Mohammad RM; Werdell J; Shekhar PV
Int J Mol Med; 1998 Jun; 1(6):915-23. PubMed ID: 9852625
[TBL] [Abstract][Full Text] [Related]
18. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.
Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA
Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186
[TBL] [Abstract][Full Text] [Related]
19. Disparity in expression of protein kinase C alpha in human glioma versus glioma-derived primary cell lines: therapeutic implications.
Zellner A; Fetell MR; Bruce JN; De Vivo DC; O'Driscoll KR
Clin Cancer Res; 1998 Jul; 4(7):1797-802. PubMed ID: 9676858
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells.
Correale P; Caraglia M; Fabbrocini A; Guarrasi R; Pepe S; Patella V; Marone G; Pinto A; Bianco AR; Tagliaferri P
Anticancer Drugs; 1995 Apr; 6(2):285-90. PubMed ID: 7540894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
